Gan & Lee Doses First Patient for Phase 1 Trial of Atopic Dermatitis Drug

Multiple Studies Advance to Phase 2b/3 as Peptide and Oligonucleotide Therapies Deliver Promising Results

A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance over 24 Weeks

Gan & Lee Pharmaceuticals - Once-Monthly Bofanglutide Maintains Improvements in Cardiometabolic Parameters

Gan & Lee Pharmaceuticals - Bofanglutide Demonstrates Favorable Safety Profile with no New Safety Signals

Guojin Research November Strategy: An Imperfect Bottom with November Stock Picks

Gan & Lee Pharmaceuticals Gets China Clinical Trial Nod for Atopic Dermatitis Treatment

Gan & Lee Pharmaceuticals Posts Higher Q3 Attributable Profit; Revenue Up

Gan&Lee Pharmaceuticals (603087.SH) Receives El Salvador Drug Registration Approval for Insulin Glargine Injection (Cartridge)

Gan & Lee Pharmaceuticals Gets El Salvador Approval for Insulin Glargine Pen

Gan & Lee Doses First Subject in Phase 1 Clinical Trial of Low Blood Protein Injection

Gan&Lee Pharmaceuticals Secures Drug Registration Approval in El Salvador for Insulin Glargine Injection (Prefilled Pen)

Gan & Lee Pharmaceuticals Gets Ethiopia Approval for Insulin Aspart Injection

Gan&Lee Pharmaceuticals Receives Ethiopian Drug Registration Approval for Insulin Aspart Injection

Gan & Lee Pharmaceuticals Gets China Approval for GLR1075 Clinical Trial; Shares Up 3%

Gan & Lee Pharmaceuticals Receives Clinical Trial Approval for Investigational Drug GLR1075 Injection

First Participant Dosed in First-in-Human Phase 1 Study of Gzc8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide Glp-1 Ra

Gan & Lee Pharmaceuticals Doses First Subject in Weight Loss Drug Trial

Gan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study

Executive Share Sales and Shifting Financial Strategies Test Gan&Lee's Transformation Path